{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:45:16Z","timestamp":1785775516789,"version":"3.56.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["09032212110006"],"award-info":[{"award-number":["09032212110006"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jctube.2026.100622","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:53:33Z","timestamp":1780628013000},"page":"100622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Acetylator status-guided rapid reintroduction of isoniazid in tuberculosis patients with drug-induced hepatotoxicity"],"prefix":"10.1016","volume":"44","author":[{"given":"Cynthia","family":"van Arkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Stemkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Magis-Escurra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Hoefsloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Carpaij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinout","family":"van Crevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jctube.2026.100622_bb0005","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.jctube.2026.100622_bb0010","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jctube.2026.100622_bb0015","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1164\/ajrccm.155.5.9154882","article-title":"Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis","volume":"155","author":"Parkin","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jctube.2026.100622_bb0020","series-title":"Antituberculosis chemotherapy","first-page":"176","article-title":"Pharmacogenetics of antituberculosis drugs","volume":"vol. 10","author":"Aarnoutse","year":"2011"},{"issue":"3","key":"10.1016\/j.jctube.2026.100622_bb0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/14622416.9.3.311","article-title":"Pharmacogenomics of anti-TB drugs-related hepatotoxicity","volume":"9","author":"Roy","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.jctube.2026.100622_bb0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/cis353","article-title":"Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy","volume":"55","author":"Pasipanodya","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jctube.2026.100622_bb0035","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jctube.2026.100622_bb0040","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5588\/ijtld.22.0188","article-title":"Clinical standards for the dosing and management of TB drugs","volume":"26","author":"Alffenaar","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.jctube.2026.100622_bb0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pupt.2011.12.001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis patients","volume":"25","author":"Magis-Escurra","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jctube.2026.100622_bb0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2014.04.019","article-title":"Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin","volume":"44","author":"Magis-Escurra","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.jctube.2026.100622_bb0055","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/jac\/dkae105","article-title":"Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations","volume":"79","author":"Stemkens","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jctube.2026.100622_bb0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2125.1986.tb02897.x","article-title":"A simple method for determining acetylator phenotype using isoniazid","volume":"22","author":"Hutchings","year":"1986","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jctube.2026.100622_bb0065","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.7326\/0003-4819-71-6-1113","article-title":"Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid","volume":"71","author":"Scharer","year":"1969","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jctube.2026.100622_bb0070","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0929-6646(09)60423-X","article-title":"Prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature","volume":"108","author":"Singh","year":"2009","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.jctube.2026.100622_bb0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00008571-199902000-00016","article-title":"Pitfalls in N-acetyltransferase 2 genotyping","volume":"9","author":"Cascorbi","year":"1999","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.jctube.2026.100622_bb0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/pds.570","article-title":"Population screening for isoniazid acetylator phenotype","volume":"10","author":"Seifart","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.jctube.2026.100622_bb0085","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2125.1988.tb03349.x","article-title":"Saliva and plasma concentrations of isoniazid and acetylisoniazid in man","volume":"25","author":"Hutchings","year":"1988","journal-title":"Br J Clin Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.jctube.2026.100622_bb0090","first-page":"139","article-title":"Molecular genotyping of N-acetylation polymorphism to predict phenotype","volume":"90","author":"Mashimo","year":"1992","journal-title":"Hum Genet"},{"issue":"9","key":"10.1016\/j.jctube.2026.100622_bb0095","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1136\/jmg.34.9.758","article-title":"A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid","volume":"34","author":"Smith","year":"1997","journal-title":"J Med Genet"},{"issue":"7","key":"10.1016\/j.jctube.2026.100622_bb0100","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jctube.2026.100622_bb0105","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1086\/650576","article-title":"Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity","volume":"50","author":"Sharma","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jctube.2026.100622_bb0110","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1086\/654806","article-title":"The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate","volume":"51","author":"Chang","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jctube.2026.100622_bb0115","doi-asserted-by":"crossref","first-page":"934","DOI":"10.5588\/ijtld.12.0782","article-title":"Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre","volume":"17","author":"Shu","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"10.1016\/j.jctube.2026.100622_bb0120","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1164\/rccm.200802-355OC","article-title":"Hepatotoxicity of pyrazinamide: cohort and case-control analyses","volume":"177","author":"Chang","year":"2008","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579426000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579426000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:54:49Z","timestamp":1785772489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579426000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"alternative-id":["S2405579426000446"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100622","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acetylator status-guided rapid reintroduction of isoniazid in tuberculosis patients with drug-induced hepatotoxicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100622"}}